Literature DB >> 22942560

Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh.

Shubha Phadke1.   

Abstract

Approximately 14,000 people with hemophilia are registered at the Hemophilia Federation of India; however, hemophilia remains under-diagnosed and many cases are not registered. In June 2009, the Government of Uttar Pradesh made anti-hemophilic factors available at a few centers, including the Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Consequently, the level of hemophilia care has improved considerably in recent times. Amongst the many challenges facing people with hemophilia, the development of inhibitors, which neutralize clotting factors provided by replacement therapy, is the most feared one. Healthcare professionals who treat people with hemophilia should not only be knowledgeable about the condition and committed to bettering the management of hemophilia, but also take responsibility for the judicious allocation of resources for various aspects of managing hemophilia. This manuscript aims to raise awareness regarding the detection and management of inhibitors in hemophilia based on the experience of a tertiary care hemophilia treatment centre in Uttar Pradesh, India.

Entities:  

Keywords:  Bypassing agents; Diagnosis; Hemophilia; India; Inhibitors management

Year:  2011        PMID: 22942560      PMCID: PMC3155716          DOI: 10.1007/s12288-011-0084-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  37 in total

1.  Factor VIII inhibitors in patients with hemophilia A.

Authors:  H Oren; I Yaprak; G Irken
Journal:  Acta Haematol       Date:  1999       Impact factor: 2.195

2.  Development of inhibitors in patients with haemophilia from India.

Authors:  K Ghosh; S Shetty; B Kulkarni; S Nair; A Pawar; A Khare; S Baindur; D Mohanty
Journal:  Haemophilia       Date:  2001-05       Impact factor: 4.287

Review 3.  The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.

Authors:  Samantha C Gouw; H Marÿke van den Berg
Journal:  Semin Thromb Hemost       Date:  2010-02-18       Impact factor: 4.180

4.  The value of early treatment in patients with haemophilia and inhibitors.

Authors:  K Kavakli; A Yesilipek; B Antmen; S Aksu; C Balkan; D Yilmaz; A Kupesiz; I Sasmaz; P Lindgren; J Mesterton
Journal:  Haemophilia       Date:  2010-01-18       Impact factor: 4.287

5.  Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.

Authors:  P L F Giangrande; J T Wilde; B Madan; C A Ludlam; E G D Tuddenham; N J Goddard; G Dolan; J Ingerslev
Journal:  Haemophilia       Date:  2009-02-01       Impact factor: 4.287

6.  Knowledge and attitudes towards haemophilia: the family side and role of haemophilia societies.

Authors:  Gouri Shanker Pandey; Inusha Panigrahi; Shubha R Phadke; Balraj Mittal
Journal:  Community Genet       Date:  2003

Review 7.  Management of haemophilia and its complications in developing countries.

Authors:  K Ghosh
Journal:  Clin Lab Haematol       Date:  2004-08

Review 8.  Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs.

Authors:  E Santagostino; M Morfini; G K-H Auerswald; G M Benson; S Z Salek; T Lambert; P Salaj; V Jimenez-Yuste; R C R Ljung
Journal:  Haemophilia       Date:  2009-09       Impact factor: 4.287

9.  International workshop on immune tolerance induction: consensus recommendations.

Authors:  D M DiMichele; W K Hoots; S W Pipe; G E Rivard; E Santagostino
Journal:  Haemophilia       Date:  2007-07       Impact factor: 4.287

10.  The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.

Authors:  C W McMillan; S S Shapiro; D Whitehurst; L W Hoyer; A V Rao; J Lazerson
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

View more
  5 in total

1.  Hemophilia in the developing world: transforming lives through international collaboration.

Authors:  A Jandial; K Mishra; R Sandal; N Jindal; D Goni; D Lad; G Prakash; A Khadwal; J Ahluwalia; N Varma; P Malhotra
Journal:  Blood Adv       Date:  2018-11-30

Review 2.  Genomics of rare genetic diseases-experiences from India.

Authors:  Sridhar Sivasubbu; Vinod Scaria
Journal:  Hum Genomics       Date:  2019-09-25       Impact factor: 4.639

3.  Rare but not Abdicated: Status of Haemophilia in foothills of Himalaya, Uttarakhand: A cross-sectional study.

Authors:  Vyas K Rathaur; N K V Vigneshwar; Ayesha Imran; Monika Pathania; Sonam Agrawal; Swathi Chacham; Prashant K Verma; Nowneet K Bhat
Journal:  J Family Med Prim Care       Date:  2021-04-08

4.  A survey of characteristics and current educational needs of hemophilia treatment centers within Asia Pacific.

Authors:  Joyce C M Lam; M Joseph John; Alison Street
Journal:  Res Pract Thromb Haemost       Date:  2018-05-24

5.  Effectiveness of a training program for bleeding disorders among accredited social health activists in Udupi District, Karnataka, India.

Authors:  Sulochana Badagabettu; Dinesh M Nayak; Annamma Kurien; Veena G Kamath; Asha Kamath; Baby S Nayak; Linu S George
Journal:  Res Pract Thromb Haemost       Date:  2018-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.